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SUMMARY 
 
   Several well documented clinical trials and retrospective studies on radiotherapy for locally 
advanced prostate cancer are reviewed showing that almost all conventional, 5-day-a-week, 2 Gy 
fraction regimes produce the “plateau effect” (further increase in total dose above some level does not 
improve local tumour control), although a few studies identified radiation dose as an important 
predictor for the treatment outcome. This suggests that conventional radiotherapy for locally advanced 
prostate cancer has limited efficacy. Dissimilar patient population in each of the reports under review 
makes conclusions uncertain because the analysis does not make it possible to separate the impact 
of clinical and histological predictors on the treatment outcome from the effect of the radiation dose. 
The advent of conformal 3D IMRT permits safe delivery of dose escalated radiotherapy. Advantages 
and traps of 3D-CRT-IMRT therapy are presented and discussed. Evidence of low α⁄β value of about 
1.5 Gy for prostate cancer cases suggests that these tumours have unusual sensitivity to a change 
in dose per fraction which opens up a new perspective for radical hypofractionated 3D-CRT and/or 
3D-high dose rate brachytherapy and various fractionation regimes. Hyperthermia combined with 
3D-CRT is discussed as an interesting treatment option.  
 
 
 
   Any discussion on treatment optimi-
zation for locally advanced prostate cancer 
(LAPC) requires a clear definition of this 
entity, which at the present time is lacking. 
Generally, local extension of the disease is 
used as a major criterion for diagnosis 
of LAPC (stage >T2, poorly differentiated 
histology and/or high PSA). When descry-
bing the treatment of prostate cancer and 
its outcome by disease burden and other 
prognostic factors, patients with LAPC are 
included in a high-risk category, which 
reflects both tumour burden and its aggre-
ssiveness. Therefore, LAPC encompasses 
patients with a stage greater than T2, 
poorly differentiated histology and/or high 
PSA level.  
   Despite that fact, there is still an active 
debate on the role and effectiveness of ra-
diotherapy (RT), either as a single mo-
dality or as a part of a combined treatment 
programme. Review of many retrospective 
studies and clinical trials shows contra-
dictive indications for RT alone, postopera-
tive RT, or RT for patients with regional 
lymphadenopathy. Concerning recent te-
chnological developments in radiotherapy 
and contemporary radiobiological studies 
on radiosensitivity of prostate cancer, 
there is a question whether conventionally 
fractionated dose escalation may increase 
therapeutic gain in terms of long-term bio-
chemical no evidence of disease (BNED). 
   This paper focuses mainly on radio-
therapy, although surgery is also briefly 
considered.  
 
Is Conventional External Beam RT 
(EBRT) a dogma for prostate cancer? 
 
   A radiation oncologist has to consider 
multiple factors when planning treatment 
strategy for prostate cancer, which 
include: technique of irradiation, appro-
priate extent of the radiation portals, 
a possibility of dose escalation, fractio-
nation schedule, and the need for surgery 
and/or hormonal therapy. Almost in all 
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the published studies, a conventional, 
5-day-a-week, fractionation schedule with 
one daily fraction is used. Because 
prostate cancer is recognized as a slowly 
proliferating tumour it is not an optimal 
candidate for accelerated, hyperfractio-
nated or hybrid treatment schedules. 
Therefore, major interest is focused on 
a possibility of obtaining therapeutic gain 
by dose escalation.  
   In 1985, Hanks et al. [1] reviewed 
574 LAPC cases treated between 1973-
1975 and found a significant dose-res-
ponse effect for T2 and T3 but not for T0, T1 
and T4 tumours. Recently, Valicenti et al. 
[2] pooled together 1,465 cases of the 
LAPC of four Radiation Therapy Oncology 
Group (RTOG) phase III trials and found 
Gleason score (GS), not the radiation 
dose, to be the strongest predictor 
of overall and disease free survival. 
The same study demonstrated the incre-
ase in GS from 2 to more than 10, which 
resulted in a significant decrease in the 
10-year survival from 85% to 43%, res-
pectively, (Fig. 1). For patients with GS 
from 8-10, further data analysis showed 
the relative risk of death from LAPC 
decreased by 29% if the total radiation 
dose is higher than 66 Gy. 
   In a study of 1,127 stage T1-T4 LAPC 
patients treated at the MD Anderson 
Cancer Center in Houston, Texas between 
1987-1997, Pollack et al. [3] found 
radiation dose-response effect (Fig.2) and 
a substantial increase in the 4-year BNED 
status for moderate risk patients. These 
patients presented with one of the follo-
wing factors: T>2 or PSA ≥ 10 ng/mL 
or GS ≥ 7. Among the above four pre-
dictive factors, only total radiation dose 
was found as an independent predictor 
for BNED. In the low-risk group no gain 
in the BNED from dose escalation 
has been detected and a total dose 
of 67-77 Gy was proposed as an adequate 
treatment for patients with pretreatment 
PSA < 10 ng/mL. For the high-risk group 
no sustained BNED at doses lower then 
80 Gy was noted. Therefore, this group 
of patients for optimal therapy requires 
a higher dose than 80 Gy, including whole 
pelvic irradiation, with or without androgen 
deprivation.  
 
 
Figure 1. Correlation between Gleason score and 10-year overall survival of patients with LAPC (according to Valicenti at al., 2) 
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Figure 2. Dose-response relationship for locally advanced prostate cancer with conventional standard radiotherapy (S, open 
circle) compared with  3D-CRT, IMRT (squares). Bottom curves represent incidence of late  bladder and rectal complications 
(LE) for respective techniques of irradiation. Dashed area reflects variations in dose and respective BNED for favourable 
and unfavourable LAPC. 
Dose curves were estimated from the reported data sets (1 – Pollack et al.; 2 – Hanks et al.; 3 – Valicenti et al. and “squares”-
Lyons et al., Hanks et al., Zelefsky et al.). 
 
   Fiveash et al. [4] reviewed outcomes 
of LAPC patients (T1-T4) with GS 8-10, 
which were treated at 3 institutions. 
The authors found by univariate analysis, 
radiation dose as the only factor predictive 
for overall survival. In multivariate ana-
lysis, however, only T-stage was a good 
predictor of overall survival. A more 
detailed analysis of subgroups of patients 
showed again RT dose and pretreatment 
PSA level as the only independent 
predictors of the overall survival.  
   Lyons et al. [5] subdivided the data 
of 738 patients from the Cleveland Clinic 
in Cleveland, Ohio into two subgroups: 
1. favorable (T1-T3, pretreatment  
PSA ≤ 10 ng/mL, GS ≤ 6) and 2. un-
favorable (T3, PSA > 10 ng/mL, GS ≥ 7). 
There was no statistical difference 
in BNED among patients receiving 74 vs. 
78 Gy. On the other hand, the tendency 
of the increase of 5-year BNED with dose 
escalation was observed in both groups. 
This gain was significant and twice as high 
for the unfavourable rather than the favou-
rable group (34% vs. 17% gain in BNED).  
   The presented, above results are con-
fusing and their interpretation is very 
difficult. Some published reports support 
whereas others raise relevant questions 
about the dose-response effect in prostate 
cancer [6]. This makes any conclusion 
concerning dose effect uncertain. 
The main reason for this uncertainty is 
a dissimilar patient population in each 
published report. This includes differences 
in T-stage, PSA level and GS. As a result, 
the analysis does not allow separating the 
impact of clinical and histological pre-
dictors on treatment outcome from 
the effect of the radiation dose. Therefore, 
the role of dose escalation for low and 
high-risk patients remains undefined. 
The Lyons et al. study [5] showed that 
dose escalation plays an important role 
for intermediate risk group patients. 
Whereas, for low-risk groups, PSA and GS 
have about twice the impact on BNED 
than does the increase in the total dose. 
   A compilation of the results in Figure 2 
(solid line) shows the “effect plateau” 
for the dose-response above 70 Gy, which 
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is graphically similar to that noted for squa-
mous cell carcinoma of the head and neck 
region. However, the nature and the origin 
of this effect for both of these tumours 
seem to be quite different. In contrast 
to squamous cell carcinoma, prostate can-
cer is classified as a slow proliferating tu-
mour, and there is no convincing evidence 
for accelerated repopulation occurring du-
ring the course of radiotherapy. Therefore, 
it is hard to believe that radiation dose 
plateau may be the result of intensive 
tumour clonogen repopulation, which ba-
lances the increase in total dose accom-
panied by the extension of overall treat-
ment time (OTT). There should be some 
other mechanism(s) involved producing 
the dose plateau, which will be discussed 
later. Irrespective of the exact mechanism 
explaining the dose plateau and based 
on the available data, there is no doubt 
that conventionally fractionated EBRT can 
produce limited benefit. However, this be-
nefit does not increase with an additional 
radiation dose and only extends the du-
ration of patient treatment course. This, 
in turn, may increase the risk of late 
toxicity without improving long-term BNED. 
 
 
Postoperative EBRT – immediate 
or delayed 
 
   Radical prostatectomy (RP) is generally 
used as a primary treatment for clinically 
localized tumours. This treatment in a pro-
spective randomized trial comparing RP 
and watchful waiting resulted in a sig-
nificant reduction of the disease specific 
mortality but did not improve overall 
survival [7]. Based on this and other 
studies, RP has become a “gold” standard 
therapy for patients with localized PC. 
The role and timing of postoperative RT is 
yet to be defined and is the source of ma-
ny controversies. At the present time, it is 
still not apparent which subset of patients 
may benefit from early (adjuvant) or de-
layed (salvage) radiotherapy [8,9]. 
   The pretreatment PSA > 10 ng/mL and 
GS ≥ 7 are the factors that most con-
sistently predict the disease recurrence. 
Lowe and Lieberman [10] added two more 
factors, i.e. positive surgical margins 
and/or seminal vesicle invasion to identify 
pT3N0 patients at high risk for early PSA 
failure. There are a few more important 
factors such as: GS in pretreatment biopsy 
compared with GS in the surgical speci-
men, capsular and/or extracapsular inva-
sion and regional lymph node involvement, 
which are likely to play an important 
prognostic role. The authors of the above 
study defined a low and high-risk of relapse 
at 5-years after RP (9.8% vs. 41.2%). 
Those in the high-risk group (pT3a,b; GS ≥ 7, 
pretreatment PSA > 10 ng/mL ; 2 positive 
margins) may benefit from adjuvant 
radiotherapy. Similar data was reported 
by other investigators [9-15]. 
   Table 1 summarizes some of the repor-
ted clinical studies and shows that adju-
vant EBRT provides a higher BNED rate 
than RP alone. In contrast, Anscher et al. 
[16] found no difference in the 10-year 
actuarial survival (52%) for both RP alone 
and adjuvant EBRT. The reason for this 
lack of difference is very likely due to the 
patient selection for adjuvant EBRT. 
These patients almost certainly had 
a more advanced disease at diagnosis 
that those treated with RP alone. Studies 
presented in Table 1 and many other 
published reports showed no dose-
response effect similar to that of EBRT 
alone. This effect is irrespective of the 
conventional radiotherapy technique and 
radiation dose levels used with or without 
a boost. Valicenti et al [17] and Leibovich 
et al. [18] using matched-pair analysis 
detected for adjuvant EBRT about 20% 
overall improvement in recurrence–free 
survival across all patient categories.  
   Some investigators suggested that 
the higher incidence of local tumour 
control after adjuvant EBRT did not 
correlate well with a decreased incidence 
of distant metastasis. This was presumed 
to be due to the presence in some patients 
of micrometastasis at the time of initial 
therapy. More recent published reports, 
however, [8,19] showed an improvement 
in biochemical control rates disproving 
the hypothesis of micrometastasis. These 
reports also recommended the need 
for a longer follow-up to demonstrate 
a reduction in the incidence of distant 
metastasis. 
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Table 1. Selected results of adjuvant EBRT for T3N0 prostate cancer compared with prostatectomy alone (> 3 yr. BNED) 
(according to Valicenti et al. 8) 
 
No pts. 
Adjuvant 
EBRD 
(total dose) 
Progression 
free rate 
BNED 
Author 
33 no 64 %* 
17 yes (60 – 66 Gy) 94 %* 
Morgan (13) 
 
91 
 
no 
 
43 % 
 
Stein (14) 
24 yes (55 – 60 Gy) 75 %  
 
228 
 
no 
 
40 % 
 
Schild  (15) 
60 yes (57 – 68 Gy) 57 %  
 
36 
 
no 
 
55 % 
 
Valicenti (8) 
36 yes (59.4 – 70.2 Gy) 88 %  
 
* follow-up of 11 months 
 
   The most important problem facing 
urologists and radiation oncologists when 
evaluating patients with pT3N0 tumours is 
the difficulty in making the two key 
decisions. These decisions relate to whe-
ther a patient should receive adjuvant 
EBRT and what should be its timing 
following RP [20]. In other words, should 
a patient receive immediate adjuvant 
EBRT or should a wait and watch policy 
be adopted. The latter approach seems 
justifiable in low-risk group patients with 
PSA < 10 ng/mL, GS ≤ 6 and negative 
surgical margins. A recent report pre-
senting long-term results, however, does 
not support the wait and watch approach 
due to a relatively poor treatment res-
ponse (20%) obtained with salvage EBRT 
in this group of patients [20]. Many studies 
on delayed EBRT as a salvage therapy 
show that such a policy might be useful in 
patients without seminal vesicle 
involvement, and in those with PSA lower 
than 1.1 ng/mL at initiation of irradiation.  
   Generally, there is no dose-response 
effect observed for the conventional EBRT 
alone or RT given following prostatectomy, 
although a few studies identified pre-
treatment PSA and radiation dose as 
independent predictors of the BNED.  
Majority of the published reports consist 
of retrospective studies and include 
heterogeneous groups of patients, making 
an attempt to identify a dose response 
effect a very difficult task. Among com-
pleted randomized trials only one seems 
to support the dose-effect relationship [3]. 
It is apparent to radiation oncologists that 
radiation dose is an important parameter. 
Otherwise, there will be no good reason 
to plan the patient for a course of irradia-
tion. However, despite a few decades 
of clinical experience and many studies 
performed, there is no convincing eviden-
ce of dose escalation effect. It appears 
that any meta-analysis studies may not be 
useful to attempt and the interpretation 
of already published studies would be 
difficult and uncertain due to a simple 
basic fact. To date, there is no consensus 
on the definition of the end-point for 
biochemical complete response after com-
pleting the treatment and there is a wide 
range of definitions of biochemical progre-
ssion. For a complete biochemical regre-
ssion PSA level as the end-point is used in 
the range of 0.0 – 0.4 ng/mL. Many 
authors suggest that the most important 
factor in defining biochemical regression is 
the magnitude of the decrease in the PSA 
level. As an example, it should make a 
difference whether PSA decreases from 
>20 ng/mL to zero compared with a de-
crease from <10 ng/mL to 0.4 ng/mL [17]. 
The end-point for biochemical progression 
is even more difficult to define because it 
differs from study to study. It ranges from 
a low of >0.05 to a high of 2.0 ng/mL or it 
is used in a nonparametric scale, requiring 
from two to three rises in the PSA level, 
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or it is based on so-called panel con-
sensus [11,14-16]. If we agree that PSA 
elevation predicts treatment failure and 
disease progression, it does not, however, 
indicate whether the recurrence is strictly 
localized or involves subclinical meta-
stasis. 
   An interesting study of Zagars and 
Pollack [21] presented modified prognostic 
groups based on biochemical relapse 
hazard (Table 2). This proposed model 
may become a useful guideline for treat-
ment strategy, but uncertainty immediately 
arises concerning the potential for tumour 
grading errors. Roberts and Roach [22], 
who performed careful analysis of biopsy 
and pathological staging data, found about 
50% of low-grade tumours undergraded, 
a 15% chance of under- and a 10% 
chance of overgrading for intermediate 
grade tumours and about 25% of high-
grade tumours being undergraded.  
 
Table 2. Biochemical relapse hazard groups of the LAPC according to Zagars and Pollack (21) 
 
Hazard 
group 
T 
stage 
Pretreatment 
PSA in ng/mL 
Gleason  
Score 
T1 – T2 ≤ 4 2 – 6 
 
T1 – T2 ≤ 4 7 – 10 
 
T1 – T2 4 < - ≤ 10 2 – 7 
 4 < - ≤ 10 8 – 10 
 10 < - ≤ 20 2 – 7 
T3 ≤ 4 - ≤ 10 2 – 10 
 10 < - ≤ 20 2 – 7 
T1 – T3 10 < - ≤ 20 8 – 10 
I 
 
II 
 
III 
 
 
IV 
 
UNFAVOURABLE 
 > 20 2 – 10 
 
 
   Based on the published data, there is 
convincing evidence of the “plateau effect” 
for the conventional EBRT alone or for ad-
juvant radiotherapy following prostatec-
tomy. As discussed, there is, however, no 
clear definition of the end-point for bioche-
mical complete regression or biochemical 
progression. For the past few decades, 
in conventional EBRT, clinicians favoured 
a uniform dose distribution within the de-
signated target volume and for dose 
escalation protocols in patients with LAPC. 
In fact, prostate cancer is a clinically hete-
rogenous tumour even within the same 
TNM stage. Histologically, there is a good 
recognition of tumours having different cell 
patterns and cell density. Therefore, 
at the present time we are confronted 
in LAPC with more dilemmas than 
dogmas. 
 
Pathologic uncertainties  
   It is extremely difficult to evaluate the re-
sults of single or combined treatment 
modalities if precision of predictive power 
of PSA and Gleason Score is uncertain. 
In the era of genetic, molecular markers 
and some very specific and sensitive tests, 
i.e. RT-PCR, there is a question whether 
the most frequently used factors predicting 
prognosis such as PSA and GS still 
remain useful in the clinic. This question 
becomes of particular relevance because 
of the fact that needle biopsy is the pre-
ferred diagnostic method in patients 
suspected of having PC. The difficulty not 
only stems from the small amount of tissue 
available for examination through a needle 
biopsy but also because of the histological 
signs of malignant disease can be subtle, 
increasing the risk of imprecise diagnosis. 
Many histological pictures seen in benign 
disease may mimic cancer leading to an 
erroneous diagnosis of malignancy with all 
its implications. There is evidence that 
positive staining of α-methylacyl-CoA 
racemase (AMACR) may increase con-
fidence in the diagnosis of prostate cancer 
[23]. The degree of diagnostic uncertainty 
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increases with the knowledge that from 
33 to 45% of Gleason scores are under-
estimated, while in 4 to 32% of patients 
GS is overestimated based on biopsy 
material comparing with Gleason score, 
which is based on the surgical specimen 
[24]. The assessment of GS is difficult 
because histological pattern of the tumour 
is to a large extent heterogeneous. 
A tumour that is mostly GS 3 with less 
amount of pattern 4 has GS 7, as does 
a tumour that is mostly pattern 4 with 
a lesser amount of GS 3. The latter is 
associated with a worse prognosis than 
the former one and it probably requires 
a more aggressive treatment. Because GS 
grading is subjective and difficult to esta-
blish based on a limited amount of tissue 
obtained via a biopsy, there may be 
a need to obtain more than one biopsy. 
Typically, biopsy samples are obtained 
with at least 6 cores, with the length 
of a core at about 15 mm. In addition, 
a second pathological review of GS may 
also be very useful.  
   Kranz et al [25] stated that the expe-
rience of a pathologist is a major deter-
minant of an accurate tumour grading. 
Otherwise, since the diagnosis is not 
certain, treatment becomes problematic 
and it may be another source of a dilemma 
when the treatment results are being 
evaluated. The use of special instructions 
in prostate cancer diagnosis for 916 pa-
thologists increased the precision of Glea-
son scoring by about 12% [25]. However, 
despite all of these doubts and uncer-
tainties predictive and prognostic value 
of PSA and GS have not been questioned 
in any of the published studies.  
 
Advantages of conformal (3DCRT) 
and dose intensity modulated (IMRT) 
radiotherapy  
 
   During recent years, technological inno-
vations in computers and in imaging 
modalities helped to develop precise 
three-dimensional treatment planning, 
beam’s eye view displays, computing and 
displaying reconstructed radiographs from 
digital CT data sets, dose-volume histo-
grams (DVHs) and multileaf collimators 
(MLC) allowing for the individual conformal 
beam shaping. The advantage offered by 
3DCRT and IMRT over conventional RT is 
an improvement of target coverage, avoi-
dance of critical normal tissues, individual 
field shaping, decrease in positioning 
errors and translation of DVH(s) into bio-
logically normalized DVH (BNDVH) and 
probability of tumour cure (TCP) and 
of normal tissue complications (NTCP). 
Actually, the IMRT is the most precise 
method of individually modified dose 
intensity and heterogenous dose delivery 
within the designated target. 
   There is still not enough outcome data 
with sufficiently long follow-up, which 
would allow to precisely and objectively 
evaluate the effectiveness of 3DCRT and 
IMRT. Results of the published studies by 
Lyons et al. [5], Hanks et al. [1] and 
Pollack et al. [3] show that compared with 
conventional RT about 10-15% gain 
in BNED can be expected (Fig. 2: dashed 
line). The other two large RTOG and 
Medical Research Council (MRC) phase III 
trials are still ongoing. On the other hand, 
Dearnaley et al. [26], Koper et al. [27] 
and Zelefsky et al. [28] found that 
3DCRT/IMRT significantly (10–15%) redu-
ced grade II and III gastrointestinal and 
genitourinary late toxicity. Zelefsky et al. 
[28], using IMRT with dynamic MLC, noted 
a significant (16%) decrease in the inci-
dence of treatment related acute rectal 
toxicity. This incidence decreased from 
61% for conventional EBRT to 45% 
in patients treated with IMRT. It is even 
more important to note that late grade II/III 
rectal bleeding decreased from 13% 
for conventional RT to 0.5% for those 
treated with IMRT (Fig. 2 - bottom curves). 
   The results of the recent studies discu-
ssed above showed that LAPC patients 
with the intermediate risk factors are most 
likely expected to benefit from 3DCRT 
/IMRT dose escalation. Patients with low 
risk factors and early stage of the disease 
may have target volume small enough that 
conventional RT is adequate to eradicate 
the tumour. For the high-risk group 
the role of the 3DCRT/IMRT is yet to be 
defined. An interesting observation may be 
obtained from Figure 2. Although, dose-
response curves (dashed lines) for 3DCRT 
/IMRT are indirectly drawn from the recen-
tly published data they are steeper than 
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those for conventional RT and the plateau 
is reduced. This factor seems to be one 
of the promising advantages of the CRT 
/IMRT. The dashed area suggests a range 
of doses instead of a single dose for a gi-
ven TCP and it reflects variation in PSA, 
GS and T stage. Simultaneously, NTCP 
curves for late effects became flattened 
for the IMRT as theoretically predicted. 
It clearly illustrates a larger “safely 
window” offered by the IMRT (delivery 
of a higher dose with a lower risk of late 
effects).  
   However, geographical miss, even 
small, during contouring the target is a ma-
jor potential problem for the IMRT, and it 
may erase the expected benefit. A decree-
ase in the radiation dose in 1% of the tar-
get’s volume decreases TCP even to zero. 
This justifies the 3DCRT/IMRT require-
ment for utmost precision and careful step-
by-step treatment planning including 
double-checks, quality assurance process 
and careful treatment delivery. 
 
Radiobiological Advantages 
 
   Bladder and rectum are the organs, 
which always need to be identified 
in the process of treatment planning. It is 
of critical importance to exclude from 
the therapeutic dose of radiation as much 
volume of these organs as it is viewed 
safe. Because these two organs are 
characterized by a threshold, dose-volume 
curve much higher dose than the 
“conventional” 60 Gy tolerance dose can 
be safely given to a smaller volume. 
This represents the key benefit of IMRT. 
However, it should be remembered that 
different parts of an organ may have very 
different local functional radiosensitivity 
and, therefore, such mini-volumes should 
be avoided by more precise IMRT 
planning. At the present time, without fun-
ctional PET and dose-function histograms 
(DFV) this goal may not be realistic. 
   Optimization of radiotherapy for carcino-
ma of the prostate is mainly discussed 
through the dose escalation (simple 
increase in the total dose) and/or new 
methods of irradiation such as 3DCRT 
or IMRT. Until recently, little attention has 
been paid to the potential benefit of alte-
ring fractionation schedules because PC 
has been recognized as a slowly growing 
tumour with a low potential for accelera- 
ted repopulation. Although TCP curves 
for head and neck cancer and those 
for prostate cancer show similar “effect 
plateau”, their nature and origin are likely 
to be quite different. For the former 
tumours it is intensive repopulation of the 
surviving clonogens, which almost entirely 
compensates for cell kill effect of daily 
doses delivered beyond week 5-6 of treat-
ment. For prostate cancer it is unlikely that 
accelerated repopulation may influence 
the TCP plateau. Recent analysis of a lar-
ge body of clinical data by Fowler et al. 
[29] gave an overall estimate of a very low 
α⁄β ratio of 1.49 Gy (95% CI of 1.35–1.63 Gy) 
for prostate cancer (patients with “inter-
mediate risk” with a PSA 10-20 ng/mL, 
GS > 6). This very low value for α⁄β may 
result from intrinsically resistant and/or 
persistent hypoxic fraction of tumour cells. 
It may also explain why LAPC is less 
responsive to the conventional fractiona-
tion with 1.8 – 2.0 Gy daily, and why 
above 70–75 Gy the “effect plateau” 
occurs (surviving hypoxic cells poorly 
respond to 2 Gy fractions). This, in turn, 
suggests that prostate cancer has unusual 
sensitivity to a change in dose per fraction 
favouring the use of hypofractionation 
to improve the therapeutic ratio.  
   For α⁄β of 10 Gy which is usually 
accepted for carcinomas, dose-fractio-
nation escalation would not produce 
significant improvement in local control 
(Fig. 3), whereas, an α⁄β of 1.5 Gy, 
as suggested by several studies, would 
predict significant and large local benefit. 
Among a few dose-per-fraction escalation 
schemes designed by Fowler et al. [29] 
(Fig. 4) the schedule of 10 x 4.68 Gy 
seems most promising because of the pre-
dicted increase in TCP but also a 14% 
decrease in the incidence of late effects. 
However, some caution should be applied 
since a decrease in the overall treatment 
time and the increase in dose accu-
mulation per week could likely result 
in a significant increase in acute toxicity. 
Therefore, clinical testing of such hypo-
fractionated schedules requires a careful 
monitoring of acute effects and late effects 
to assure that clinical results meet 
the expectations. It is apparent that there 
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is a need for long-term follow-up and 
a clear definition of end-point of tumour 
control and tumour progression. What is 
also particularly attractive is that 3D-real 
time high-dose rate brachytherapy (3D-
CHDRBT) can effectively be used alone 
as a treatment for PC or be used as 
a boost. 
   Conformal high dose rate (HDR) RT 
provides an accurate increase in the dose 
delivered to the prostate without signi-
ficantly affecting adjacent normal tissues. 
Real-time guidance makes it possible 
to generate a steep dose gradient be-
tween the target and critical organs that 
may become unaffected by organ motion 
or setup uncertainties. Experience of the 
Sloan Kettering Memorial Cancer Center 
in New York [28] and a similar experience 
of a few European Centers suggest that 
in the near future hypofractionated IMRT 
and/or 3D-C HDR BT can be selectively 
used with PET guided hypoxic (or intri-
nsically resistant) parts of the tumour. 
This will be the beginning of real “dose 
painting”. 
 
Figure 3. Predicted biochemical no evidence of disease (at 5 yrs.) in relation to dose escalation (NTD) calculated for α⁄β = 3 Gy 
(representing late responding tissues). Note that if the α⁄β for prostate cancer would be as high as 10 Gy the schemes do not 
predict significant increase in tumour control, whereas, for α⁄β = 1.5 Gy local control benefit is pronounced (according to Fowler, 
29). 
Figure 4. Example of dose-fractionation escalation schemes increasing tumour control while maintaining a-constant late effects. 
Square shows clinically feasible scheme (Fowler, 29).  
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Hyperthermia perspectives  
 
   Hyperthermia (HT) is a treatment, which 
increases the temperature of the desig-
nated tumour bearing volume to 41-430C. 
The anti-tumour effects of HT have been 
known since the antiquity, but modern 
applications of this therapy date back 
to the 1970s. There is a strong and very 
well documented biological rationale 
for the use of HT in combination with RT 
and/or chemotherapy (CT) [30,31]. 
The exact biological mechanism of HT 
action as a part of mutidiciplinary treat-
ment approach in cancer is beyond 
the scope of this paper. It needs to be 
stated, however, that for the optimal 
effectiveness HT-RT and/or CT need to be 
given in an appropriate sequence and du-
ration [32]. HT is usually given as a part 
of combined management in patients with 
locally advanced and/or recurrent tumours 
[30,31]. Multiple randomized trials con-
ducted over the past decade have clearly 
demonstrated the effectiveness of HT-RT 
combination over that of RT alone in terms 
of significant improvement in the incidence 
of local tumour control rates and survival 
[30,31,33-36]. Over the past quarter 
of a century clinical HT suffered as a result 
of technical problems relevant to a precise 
energy deposition in the designated tu-
mour bearing area. A related problem was 
due to a frequently imperfect methodology 
of temperature measurements. It is appa-
rent that the existing HT technology is 
primarily capable of heating optimally 
small volumes of tissue in superficial 
tumours. Deep regional HT requires much 
work to optimize this important treatment. 
Improved temperature distribution was 
reported with the use of a more advanced 
BSD-2000 deep HT system [37,38]. 
   The use of adjuvant HT in addition to RT 
for PC has infrequently been reported. 
This was due to the above noted difficulty 
of heating deep-seated tumours such that 
of the prostate. A report on the use 
of deep regional HT was published as 
a part of multi-center phase I-II trials 
of 352 patients, which included 20 PC 
[39,40]. All of these 20 PC patients 
presented with locally advanced recurrent 
and/or persistent tumours following 
definitive RT. It is of interest to note that 
patients with PC had greater probability 
of complete and partial response than 
those with other diagnoses. The above 
reports clearly demonstrated the difficulty 
with the use of HT instrumentation 
designed in the 1980s for deep regional 
treatments [41]. 
   Intracavitary HT using the transrectal 
route has been under study to improve 
temperature deposition in the prostate and 
decrease the incidence of HT related 
acute morbidity related to the use of deep 
regional HT [42,43,44]. Of a considerable 
interest is an unexpected effect of HT 
on cell-mediated immunity [42,44]. 
This effect, if proven in other studies, 
could be utilized in designs of future HT 
trials in patients with PC. Recently 
published reports suggest HT regulated 
and enhanced gene therapy, which may 
also be of major interest for designing 
future clinical trials [45,46]. 
   The work at The University of Southern 
California (USC) in Los Angeles, California 
and The University of Leuven in Leuven, 
Belgium demonstrated good prostate 
heating with the use of transrectal and 
transurethral microwave HT [47-49]. It is 
apparent that major effort needs to be 
undertaken to design prospective rando-
mized trials comparing radiotherapy alone 
with RT-HT combination in locally advan-
ced adenocarcinoma of the prostate. 
The outcomes of these future trials will 
define the role of HT in the management 
of patients with this tumour. 
 
Molecular and genetic prediction 
 
   Currently more studies concentrate 
on the predictive value of oncogene 
expression and on molecular markers [23]. 
Because prostate cancer is a relatively 
slowly growing tumour it appears that 
genes controlling tumour redistribution and 
proliferation may not be of primary 
interest. We should concentrate more on 
tumour hypoxia, tumour metastatic poten-
tial (E-Cadherin, CD44, nm23), chronic 
inflammation (Cox2) and apoptosis 
(TP 53, Rb1, bax/bcl2). Wider application 
of hyperthermia in the clinic may lead 
to increasing interest in heat shock pro-
teins (hsp 70). Most of the recent studies 
show, however, that there is not a single 
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genetic or molecular predictor. It is most 
likely that complex configuration of a few 
of these parameters may reveal an im-
portant predictive value. All genetic and 
molecular studies show that prostate can-
cer is composed of heterogenous cell 
population, which differs significantly even 
within the same clinical stage, GS or PSA 
level. Although gatekeeper genes have not 
yet been identified, they may represent 
a new and exciting frontier in our know-
ledge. The search for these genes is ex-
pected to be difficult and require con-
siderable resources to process numerous 
serum and tissue samples.  
 
Summary 
 
   Diagnosis of prostate cancer is a very 
complex process. Many benign histolo-
gical patterns may mimic the histological 
appearance of prostate cancer, which 
in turn may result in serious implications. 
Despite all the discussed uncertainties, 
PSA, GS and tumour stage remain widely 
used and reliable predictors of treatment 
outcomes. Except for cases in the early 
stage of the disease with “low-risk” factors, 
conventional EBRT has limited efficacy 
because of the “plateau effect”, which 
probably represents tumour persistent 
hypoxia and resistance. Because prostate 
cancer is a heterogenous tumour with 
important differences in its characteristics 
(even within the same stage, GS and PSA 
level) regarding cell density, hypoxia, 
apoptosis potential, and local inflammation 
the treatment of this entity needs to be 
highly individualized. Radiotherapy treat-
ment planning should be designed 
for each patient with heterogeneous dose 
distribution. The major dilemma is our 
limited understanding of the pattern of he-
terogeneous cell distribution. It seems 
likely that PET and molecular mapping 
may be of help to resolve this problem 
in the near future. The main lesson we 
learned from over two decades of con-
ducting clinical studies is the dose escala-
tion above 70-75 Gy using conventional 
2 Gy daily fractions does not produce 
a significant benefit. On the contrary, 
it may increase the risk of development 
of severe late complications. Evidence 
of low α⁄β value of about 1.5 Gy for pro-
state cancer suggests that these tumours 
have unusual sensitivity to a change 
in dose per fraction and therefore hypo-
fractionated EBRT and/or 3D-high dose 
rate brachytherapy could be more effective 
than the conventional irradiation. Despite 
the diagnostic and tumour biology 
uncertainties prostate cancer patients are 
excellent candidates to consider for 3D-
conformal and dose intensity modulated 
radiotherapy with or without 3D-HDR 
boost dose painting. These are attempts 
to escalate the dose selectively to the tu-
mour and to spare critical neighbouring 
normal tissue. Hyperthermia with radio-
therapy may become an interesting 
treatment option for selected patients with 
PC when PET-hypoxia mapping will 
become available in the clinic. 
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